Present Phase 1 data for Belcesiran
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- July 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“data to be presented in 2021”
What we found
Evidence strength A What the grades mean
The company announced interim Phase 1 data for Belcesiran in July 2021 and planned further presentations for November 2021, fulfilling the commitment to present data within 2021.
-
A Dicerna Pharmaceuticals Inc 10-Q filed 2021-11-09
“Data from an interim analysis announced in July 2021 of the four completed active-treatment dose cohorts (0.1, 1.0, 3.0, and 6.0 mg/kg) showed dose-dependent reductions in serum AAT” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Belcesiran Phase 1 data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Dicerna Pharmaceuticals Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C399529-021904 · Corrections policy